Clinical Trials for Non-Small Cell Lung Cancer

NECTINIUM-2: A Phase 1b, 2 Part, Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of a Nectin-4 Radiopharmaceutical ([225Ac]Ac-AKY-1189) in Patients With Previously Treated Locally Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial is enrolling adults with previously treated, locally advanced or metastatic solid tumors (including urothelial carcinoma and other Nectin-4–positive types) who have measurable disease and good performance status. Patients receive [225Ac]Ac-AKY-1189, an investigational Nectin-4–targeting radiopharmaceutical that delivers actinium-225 directly to tumor cells, in up to six cycles following Nectin-4 PET imaging confirmation.

ClinicalTrials.gov ID: NCT07020117

A Phase 1, Open-label Study of Oral BDTX-4933 in Patients With KRAS, BRAF and Other Select RAS/MAPK Mutation Positive Neoplasms

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors—such as NSCLC (KRAS non-G12C), melanoma (BRAF/NRAS), histiocytic neoplasms, thyroid carcinoma, colorectal carcinoma (BRAF Class II/III), or other BRAF-mutant tumors—who have exhausted standard therapies, to receive oral BDTX-4933, a brain-penetrant RAF/RAS clamp inhibitor targeting a range of RAS/MAPK pathway mutations. The study includes dose escalation and expansion phases to assess safety and preliminary efficacy.

ClinicalTrials.gov ID: NCT05786924

A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults With Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic hepatocellular carcinoma or squamous-cell non-small cell lung cancer who have progressed after at least one prior systemic therapy (including immune checkpoint inhibitors and platinum-based chemotherapy for NSCLC), and randomizes patients to receive intravenous ABBV-324 (investigational agent with undisclosed mechanism) or lenvatinib. Both dose escalation and optimization phases are included, with ABBV-324 given as monotherapy.

ClinicalTrials.gov ID: NCT06858813

An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumour Activity of WEF-001 in Participants With Advanced KRAS- Mutant Solid Tumours.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic KRAS‑mutant solid tumors (e.g., PDAC, CRC, NSCLC, platinum‑resistant serous ovarian, cholangiocarcinoma, urothelial) after at least one prior therapy, ECOG 0–1, receive WEF‑001 monotherapy. WEF‑001 is a first‑in‑class macropinocytosis‑exploiting conjugate designed to selectively deliver a cytotoxic payload to KRAS‑mutant tumors; dose‑finding followed by expansion cohorts.

ClinicalTrials.gov ID: NCT07148128

A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable/metastatic solid tumors harboring KRAS G12V/D/C/R/A or G13D mutations or KRAS amplification (ECOG 0–1, measurable disease) receive IV ASP5834, a first‑in‑human pan‑KRAS targeted protein degrader designed to eliminate multiple KRAS variants; dose-expansion includes PDAC, NSCLC, and other non-CRC tumors. Separate colorectal cancer cohorts test ASP5834 combined with panitumumab in KRAS‑mutant mCRC after standard therapies.

ClinicalTrials.gov ID: NCT07094204

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with advanced/metastatic solid tumors lacking standard options; dose-escalation all-comers followed by expansion in biomarker-selected cohorts including NSCLC with YES1 or TYMS amplification or FAT1 mutation, renal cancer or mesothelioma with NF2 mutation, and other tumors with NF2/FAT1/LATS1 mutations or TYMS/YAP1/YES1/TAZ1 amplifications. Treatment is NXP900, an oral conformation-selective SRC family kinase inhibitor with high potency against YES1/SRC, given as monotherapy.

ClinicalTrials.gov ID: NCT05873686

A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants With Advanced or Metastatic Select Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, unresectable advanced/metastatic solid tumors (NSCLC, HNSCC, ESCC, left‑sided CRC) receive ALX2004 monotherapy, an investigational EGFR‑targeted antibody–drug conjugate carrying a topoisomerase I inhibitor payload designed for bystander effect. Excludes candidates for curative local therapy, rapidly progressive disease, short life expectancy, and prior exposure to topoisomerase I inhibitor ADCs.

ClinicalTrials.gov ID: NCT07085091

A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic solid tumors harboring KRAS alterations (any missense mutation or amplification) and no standard options receive the investigational oral pan‑KRAS inhibitor AMG 410 (dual-state, noncovalent inhibitor selective over HRAS/NRAS) as monotherapy or combined with pembrolizumab (solid tumors) or panitumumab (CRC/PDAC). Includes multiple tumor types (e.g., NSCLC, CRC, PDAC) with measurable disease and ECOG 0–1; treatment continues until progression or intolerance.

ClinicalTrials.gov ID: NCT07094113

A Multi-Center, Open Label, Phase 1/2 Study of CP-383, in Patients With Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic solid tumors lacking effective standard options (broad basket with prioritized cohorts such as CRC, SCLC, HNSCC, NSCLC, pancreatic, and bladder; some genomically enriched) receive oral single‑agent CP-383 in dose escalation and tumor‑specific expansions. CP-383 is a first‑in‑class small molecule designed to modulate lipid‑binding pockets on oncogenic proteins (exact target undisclosed).

ClinicalTrials.gov ID: NCT07030257

A Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic urothelial/bladder cancer, NSCLC, HNSCC, esophageal cancer, or pancreatic adenocarcinoma (ECOG 0–1) receive PF-08046876, an ITGB6-targeted antibody–drug conjugate delivering a topoisomerase I payload, as IV monotherapy after prior standard therapy (≤2 prior lines in Part 2). Dose escalation/optimization and tumor-specific expansions assess safety, PK, and preliminary activity; excludes prior camptothecin/topo I ADC exposure and significant GI or pulmonary comorbidities.

ClinicalTrials.gov ID: NCT07090499